Inventor

SANTORA VINCENT

US15 patents

⚠️ This page may combine multiple inventors who share the name “SANTORA VINCENT”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

AMGEN INC

9 patents

US6645990B2Nov 11, 2003

Thiazolyl urea compounds and methods of uses

AMGEN INC172 citations97

US7196104B2Mar 27, 2007

Thiazolyl urea compounds and methods of uses

AMGEN INC120 citations96

US11608344B2Mar 21, 2023

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

AMGEN INC4 citations83

US11718617B2Aug 8, 2023

Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use

AMGEN INC4 citations73

US11912711B2Feb 27, 2024

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

AMGEN INC3 citations72

US11884675B2Jan 30, 2024

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

AMGEN INC3 citations72

US12319691B2Jun 3, 2025

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

AMGEN INC0 citations61

US12252489B2Mar 18, 2025

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

AMGEN INC0 citations61

US12428425B2Sep 30, 2025

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

AMGEN INC0 citations60

DART NEUROSCIENCE CAYMAN LTD

4 patents

US9150572B2Oct 6, 2015

DART NEUROSCIENCE (CAYMAN) LTD

2 patents

US9708334B2Jul 18, 2017

Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors

DART NEUROSCIENCE (CAYMAN) LTD2 citations70

US9675605B2Jun 13, 2017

Substituted naphthyridine and quinoline compounds as MAO inhibitors

DART NEUROSCIENCE (CAYMAN) LTD1 citations61

SANTORA VINCENT

AMGEN INC

Thiazolyl urea compounds and methods of uses

Thiazolyl urea compounds and methods of uses

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

DART NEUROSCIENCE CAYMAN LTD

Substituted naphthyridine and quinoline compounds as MAO inhibitors

Substituted naphthyridine and quinoline compounds as MAO inhibitors

Substituted naphthyridine and quinoline compounds as MAO inhibitors

Substituted azetidinyl compounds as GlyT1 inhibitors

DART NEUROSCIENCE (CAYMAN) LTD

Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors

Substituted naphthyridine and quinoline compounds as MAO inhibitors